Year: 2015
Type: review
Abstract: Increased glucose metabolism in cancer cells is a phenomenon that has been known for over 90 years, allowing maximal cell growth through faster ATP production and redistribution of carbons towards nucleotide, protein and fatty acid synthesis. Recently, metabolites that can promote tumorigeneis by altering the epigenome have been identified. These 'oncometabolites' include the tricarboxylic acid cycle metabolites succinate and fumarate, whose levels are elevated in rare tumours with succinate dehydrogenase and fumarate hydratase mutations, respectively. 2-Hydroxyglutarate is another oncometabolite; it is produced de novo as a result of the mutation of isocitrate dehydrogenase, and is commonly found in gliomas and acute myeloid leukaemia. Interestingly, the structural similarity of these oncometabolites to their precursor metabolite, α-ketoglutarate, explains the tumorigenic potential of these metabolites, by competitive inhibition of a superfamily of enzymes called the α-ketoglutarate-dependent dioxygenases. These enzymes utilize α-ketoglutarate as a cosubstrate, and are involved in fatty acid metabolism, oxygen sensing, collagen biosynthesis, and modulation of the epigenome. They include enzymes that are involved in regulating gene expression via DNA and histone tail demethylation. In this review, we will focus on the link between metabolism and epigenetics, and how we may target oncometabolite-induced tumorigenesis in the future.
Source: FEBS Journal
DOI: 10.1111/febs.13295
Authors: Stefan Nowicki, Eyal Gottlieb
Institution: Cancer Research UK Scotland Institute
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: oncometabolites, cancer metabolism, epigenetics, succinic acid, fumarate, 2-hydroxyglutarate, IDH mutation, succinate dehydrogenase mutations, alpha-ketoglutarate, alpha-ketoglutarate-dependent dioxygenase, DNA demethylation, histone demethylation, carcinogenesis, glioma, acute myeloid leukemia, targeted therapy
Open Access status: hybrid
Estimated APC paid: $5,000
Funder: Cancer Research UK
Awards: G1003548837, G3172452966
OpenAlex ID: W2089060699
